Literature DB >> 9743700

Management of renal angiomyolipoma: analysis of 15 cases.

O J Kessler1, G Gillon, M Neuman, D Engelstein, H Winkler, J Baniel.   

Abstract

OBJECTIVE: We present our experience with 15 patients with renal angiomyolipoma warranting intervention.
METHODS: The medical records and radiological studies were reviewed for patient age and sex, tumor location and size, association with tuberous sclerosis, and treatment approach. All patients were regularly followed by ultrasound and computed tomography scan.
RESULTS: Presenting symptoms were retroperitoneal bleeding in 9 patients and flank pain in 6. Excluding cases of tuberous sclerosis (mean tumor diameter 11 cm), the mean diameter of the two tumors that bled was 5.4 cm, similar to those in the patients presenting with flank pain. Two patients with retroperitoneal bleeding had tumors < 3 cm. Angioinfarction was performed in 7 patients, partial nephrectomy in 3, and total nephrectomy in 4. One patient with tuberous sclerosis, who was observed only, died of bleeding and sepsis. The mean follow-up period of 4.3 years revealed stable creatinine levels and no recurrent hemorrhage.
CONCLUSIONS: The management approach of angiomyolipoma should be aimed at parenchymal preservation which can be effectively accomplished by limited surgery or preferably by selective embolization. Preventive embolization may be feasible even for small tumors. However, any doubt about the diagnosis of angiomyolipoma should be clarified by surgery.

Entities:  

Mesh:

Year:  1998        PMID: 9743700     DOI: 10.1159/000019658

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

1.  Life threatening hematuria in a patient with renal angiomyolipoma and selective renal embolization prior to nephrectomy.

Authors:  Cem Ozden Yeniyol; Nuri Zeyrek; Mustafa Parildar; Elif Selek; Funda Taşli; Ahmet Memiş
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

2.  Retroperitoneoscopic microwave ablation of renal hamartoma: middle-term results.

Authors:  Wei Guan; Jian Bai; Zhiquan Hu; Yaowu Su; Qianyuan Zhuang; Zhangqun Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

Review 3.  Tuberous sclerosis complex renal disease.

Authors:  Bradley P Dixon; John C Hulbert; John J Bissler
Journal:  Nephron Exp Nephrol       Date:  2010-11-11

4.  Surveillance imaging for sporadic renal angiomyolipoma less than 40 mm: lessons learnt and recommendations from the experience of a large district general hospital.

Authors:  K E Chan; Ecp Chedgy; C L Bent; K J Turner
Journal:  Ann R Coll Surg Engl       Date:  2018-04-16       Impact factor: 1.891

Review 5.  Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review.

Authors:  John J Bissler; John C Kingswood
Journal:  Ther Adv Urol       Date:  2016-04-06

6.  The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms.

Authors:  J L Arbiser; R Yeung; S W Weiss; Z K Arbiser; M B Amin; C Cohen; D Frank; S Mahajan; G S Herron; J Yang; H Onda; H B Zhang; X Bai; E Uhlmann; A Loehr; H Northrup; P Au; I Davis; D E Fisher; D H Gutmann
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 7.  Tuberous sclerosis complex: the past and the future.

Authors:  Liesbeth De Waele; Lieven Lagae; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2014-12-23       Impact factor: 3.714

Review 8.  Clinical and molecular insights into tuberous sclerosis complex renal disease.

Authors:  Brian J Siroky; Hong Yin; John J Bissler
Journal:  Pediatr Nephrol       Date:  2010-12-09       Impact factor: 3.714

9.  Transcatheter embolisation of renal angiomyolipoma.

Authors:  S Leong; A N Keeling; F P McGrath; M J Lee
Journal:  Ir J Med Sci       Date:  2009-07-18       Impact factor: 1.568

10.  The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

Authors:  J Chris Kingswood; Sergiusz Jozwiak; Elena D Belousova; Michael D Frost; Rachel A Kuperman; E Martina Bebin; Bruce R Korf; J Robert Flamini; Michael H Kohrman; Steven P Sparagana; Joyce Y Wu; Thomas Brechenmacher; Karen Stein; Noah Berkowitz; John J Bissler; David N Franz
Journal:  Nephrol Dial Transplant       Date:  2014-04-11       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.